This article was originally published in The Gray Sheet
Insulin device firm CeQur and liquid biopsy firm Exosome Diagnostics closed financing rounds; Abbott completes its transcatheter mitral valve replacement deal; Unilife considers its options; and Quest Diagnostics subsidiary advances infectious disease offerings.
You may also be interested in...
Business Briefs: Knee, Obesity Approvals, And A Deal Roundup
Key approvals for Stryker and Apollo Endosurgery, and deals by Boston Scientific, Illumina, Abbott and Lombard Medical.
News Briefs: Dx Bill Reintroduced; FDA Questions Guided Therapeutics’ LuViva; Study Milestones
Rep. Leonard Lance reintroduced a bill in the House to address flaws in Medicare’s reimbursement system for diagnostics. Guided Therapeutics receives more questions from FDA on the PMA for its LuViva cervical scan. Study news from InSightec, Direct Flow Medical and PLC Systems. More news.
Huma Secures EU MDR Approval For Medtech Software That Can Be Used In Any Disease
Huma Therapeutics has secured the first ever EU regulatory approval for a “disease agnostic” class IIb medtech software platform. CEO Dan Vahdat tells Medtech Insight how the product can be configured to monitor patients with any condition.